Hamet P, Gong L
Centre de Recherche Hôtel Dieu de Montréal, Université de Montréal, Québec, Canada.
J Hypertens Suppl. 1996 Sep;14(2):S123-7. doi: 10.1097/00004872-199609002-00021.
The present debate concerning the use of new classes of antihypertensive agents in general and calcium antagonists in particular, is due to the fact that for most of the agents, there is a lack of data from major clinical trials with cardiovascular outcomes. CONTRIBUTION OF CHINESE CLINICAL TRIAL DATA: The present review summarizes and qualifies the prospective clinical trial data obtained in China which were performed with calcium antagonists and indapamide. These results need to be reviewed critically for their weaknesses as well as strengths, so that the data can be used to improve present knowledge of antihypertensive therapy.
